Targeting the BLyS-APRIL signaling pathway in SLE
Copyright © 2012 Elsevier Inc. All rights reserved.
| Veröffentlicht in: | Clinical immunology (Orlando, Fla.). - 1999. - 148(2013), 3 vom: 27. Sept., Seite 322-7 |
|---|---|
| 1. Verfasser: | |
| Format: | Online-Aufsatz |
| Sprache: | English |
| Veröffentlicht: |
2013
|
| Zugriff auf das übergeordnete Werk: | Clinical immunology (Orlando, Fla.) |
| Schlagworte: | Journal Article Review APRIL BLyS/BAFF Systemic lupus erythematosus (SLE) Antibodies, Monoclonal, Humanized B-Cell Activating Factor BLyS receptor Receptors, Tumor Necrosis Factor Tumor Necrosis Factor Ligand Superfamily Member 13 mehr... |
| Zusammenfassung: | Copyright © 2012 Elsevier Inc. All rights reserved. The B lymphocyte stimulator (BLyS)-A PRoliferation-Inducing Ligand (APRIL) signaling pathway has an important role in the selection, maturation and survival of B cells and plays a significant role in the pathogenesis of systemic lupus erythematosus (SLE). The inhibition of BLyS, a survival factor for transitional and mature B cells, has recently proven to be successful in large phase III clinical trials that led to the approval of an anti-BLyS monoclonal antibody (belimumab) for the treatment of SLE. Yet, there is currently a need to both understand better the mechanisms of action of belimumab in SLE and better define the subsets of patients that are more likely to respond to the drug |
|---|---|
| Beschreibung: | Date Completed 23.10.2013 Date Revised 07.08.2013 published: Print-Electronic Citation Status MEDLINE |
| ISSN: | 1521-7035 |
| DOI: | 10.1016/j.clim.2012.11.010 |